An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year worldwide ( ) with these numbers expected to grow. The American Cancer Society ...

The Zacks Consensus Estimate for J&J’s 2025 sales and EPS implies a year-over-year increase of 2.7% and 6.2%, respectively.

Merck & Co – known as MSD outside the US and Canada – has shared promising results from a late-stage study of its anti-PD-1 therapy Keytruda (pembrolizumab) in ovarian cancer. The phase 3 KEYNOTE-B96 ...

Merck, known as MSD outside of the United States and Canada, announced that the phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, met its primary endpoint of progression-free survival (PFS) for the ...

MSD has reported that the randomised Phase III KEYNOTE-B96 trial of Keytruda (pembrolizumab) plus chemotherapy (paclitaxel), with or without bevacizumab, has met its primary goal of progression-free ...

Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ovarian cancer, including patients with PD-L1–positive tumors.

Merck says late-stage trial for Keytruda regimen hit main goal in ovarian cancer May 15, 2025 7:19 AM ET Merck & Co., Inc. (MRK) Stock RHHBY, RHHBF By: Dulan Lokuwithana, SA News Editor Play (2min) ...

RAHWAY, N.J. – Merck & Co., Inc., a global healthcare leader, announced positive results from its Phase 3 KEYNOTE-B96 trial, which could potentially lead to a new treatment option for patients with ...

Merck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. But with promising early results from a phase 3 study in certain ...

Ovarian cancer is a leading cause of cancer death among women, with an estimated 324,603 new cases and approximately 206,956 deaths globally in 2022. In the U.S., approximately 20,890 new cases ...

In the randomized, double-blind KEYNOTE-B96 trial (ClinicalTrials.gov Identifier: NCT05116189), study participants with platinum-resistant recurrent ovarian cancer (N=643) were randomly assigned ...